PRRC2B

Across TCGA pan-cancer cohorts, PRRC2B Mutation is linked to patient survival in 13 of 34 cancer types, making it a survival-associated PRRC2B data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher PRRC2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRRC2B expression acts as an unfavorable survival marker, although some lineages such as SKCM and COAD show a favorable association.

KIRP, ESCA, and KICH are the cancer types where PRRC2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.169	0.888	<.001	42	view →
ESCA	OS	Median	II,III,IV	0.108	0.687	<.001	24	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
TGCT	OS	Median	All	0.069	0.968	<.001	12	view →
SARC	DFS	Median	All	0.217	0.617	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	.001	6	view →
READ	DFS	Median	All	0.223	0.730	.006	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
LGG	OS	Median	All	0.255	0.799	.017	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	All	0.765	0.609	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

PRRC2B–KIRP (OS)

Open the KIRP breakdown →